Cargando…

Cyclophosphamide therapy for secondary amyloidosis in a patient with juvenile idiopathic arthritis unresponsive to tumor necrosis factor α inhibitor therapy

Detalles Bibliográficos
Autores principales:	Han, Sun Ae, Yoon, Young Min, Lee, Wan Soo, Kim, Yun Sung, Shin, Byung Chul, Chung, Jong Hoon, Kim, Hyun Lee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855090/ https://www.ncbi.nlm.nih.gov/pubmed/26947026 http://dx.doi.org/10.3904/kjim.2014.292

Ejemplares similares

Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
por: Lanz, Sofia, et al.
Publicado: (2021)

Juvenile idiopathic arthritis complicated by amyloidosis with secondary nephrotic syndrome – effective treatment with tocilizumab
por: Kwiatkowska, Małgorzata, et al.
Publicado: (2015)

Juvenile idiopathic arthritis treated with biological therapies
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis
por: Nelson, Meghan Corrigan, et al.
Publicado: (2023)

Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
por: Radziszewska, Anna, et al.
Publicado: (2014)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
por: Kilic, Levent, et al.
Publicado: (2018)

Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjögren's syndrome
por: Lin, Ting-Yun, et al.
Publicado: (2012)

Secondary Osteoporosis in Patients with Juvenile Idiopathic Arthritis
por: Brabnikova Maresova, Kristyna
Publicado: (2011)

Efficacy and safety of Etanercept therapy in juvenile idiopathic arthritis
por: Lazareva, Arina, et al.
Publicado: (2011)

Are we closer to personalized therapy in juvenile idiopathic arthritis?
por: Smolewska, Elżbieta
Publicado: (2016)

Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis
por: Choida, Varvara, et al.
Publicado: (2021)

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
por: Nieto-González, Juan Carlos, et al.
Publicado: (2021)

Tumor necrosis factor-alpha polymorphism and susceptibility to juvenile idiopathic arthritis
por: Bayraktar, S, et al.
Publicado: (2008)

Familial hypercholesterolemia misinterpreted as juvenile idiopathic arthritis
por: Schou, AJ, et al.
Publicado: (2011)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

Tuberculosis in Juvenile Idiopathic arthritis under Anti-TNF therapy
por: Espada, G, et al.
Publicado: (2011)

Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis
por: Semeraro, Francesco, et al.
Publicado: (2014)

Update on biologic therapies for juvenile idiopathic arthritis-associated uveitis
por: Thomas, Joanne, et al.
Publicado: (2021)

PReS-FINAL-2032: Changes in immunogenic profile in patients with juvenile idiopathic arthritis exposed to anti tumoral necrosis factor therapy
por: Guillen Astete, CA, et al.
Publicado: (2013)

Juvenile idiopathic arthritis
por: Bhatt, Krupa H, et al.
Publicado: (2014)

Juvenile Idiopathic Arthritis
por: Barut, Kenan, et al.
Publicado: (2017)

Growth retardation in patients with juvenile idiopathic arthritis and growth hormone therapy
por: Nikishina, I, et al.
Publicado: (2008)

The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
por: Alfantaki, SA, et al.
Publicado: (2011)

Surgical Treatment of Juvenile Idiopathic Arthritis in the Era of Novel Drug Therapies
por: Klein, Céline, et al.
Publicado: (2023)

Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature
por: Jung, Ju-Yang, et al.
Publicado: (2021)

Insurance Delays in Initiation of Tumor Necrosis Factor Inhibitors in Children With Juvenile Idiopathic Arthritis
por: Roberts, Jordan E., et al.
Publicado: (2022)

Juvenile idiopathic arthritis: Diagnosis and differential diagnosis
por: Kim, Ki Hwan, et al.
Publicado: (2010)

Progressive outer retinal necrosis after rituximab and cyclophosphamide therapy
por: Dogra, Mohit, et al.
Publicado: (2018)

Atherosclerosis in Juvenile Idiopathic Arthritis
por: Jednacz, Ewa, et al.
Publicado: (2012)

Juvenile idiopathic arthritis classification
por: Martini, Alberto
Publicado: (2014)

Phenotypes of juvenile idiopathic arthritis
por: Rokhlina, Faina, et al.
Publicado: (2014)

The joints in juvenile idiopathic arthritis
por: Ording Muller, Lil-Sofie, et al.
Publicado: (2015)

Ultrasound in juvenile idiopathic arthritis
por: Magni-Manzoni, Silvia
Publicado: (2016)

Haptoglobin in Juvenile Idiopathic Arthritis
por: Berntson, Lillemor, et al.
Publicado: (2022)

Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis
por: Swart, Joost F, et al.
Publicado: (2018)

How do parents of children with juvenile idiopathic arthritis (JIA) perceive their therapies?
por: Rouster-Stevens, Kelly, et al.
Publicado: (2008)

Tocilizumab therapy in systemic juvenile idiopathic arthritis – lessons of real clinical practice
por: Kaleda, Maria I, et al.
Publicado: (2014)

Presumed tubercular choroidal nodule following adalimumab therapy for juvenile idiopathic arthritis
por: Vaidya, Harshit, et al.
Publicado: (2019)

Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
por: Shibata, Tomoyuki, et al.
Publicado: (2019)

Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies
por: Horne, AnnaCarin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4kjs6u28pvhr5vjq27u6h37mhp